Urolog. pro Praxi, 2008; 9(4): 187-189

Current status of PSA in diagnosing prostate cancer

MUDr. Jiří Klečka Ph.D, MUDr. Petr Běhounek, doc. MUDr. Milan Hora Ph.D
Urologická klinika, FN a LF UK, Plzeň

The introduction of prostate-specific antigen has revolutionized the detection and management of patiens with prostate cancer. Despite this there was always been a concern among clinicians about the usefulness of total PSA level as a marker for prostate cancer. We discuss the use of calculated variables and molecular forms of PSA. The precursor forms of PSA have been associated with presence and biological behavior of prostate cancer. With recent advances in biotechnology, e. g. high-throughout molecular analyse, many potential blood biomarkers have been identified. Consequently, the future of cancer prognosis might rely on small panels of markers That can accurately predict prostate cancer presence and prognosis. PSA and its isorms will be apart of this panel.

Keywords: prostate cancer, PSA (prostatic specific antigen), tumor marker

Published: December 19, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klečka J, Běhounek P, Hora M. Current status of PSA in diagnosing prostate cancer. Urol. praxi. 2008;9(4):187-189.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol 1994; 151: 1558-1564. Go to original source... Go to PubMed...
    2. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998; 44: 1216-1223. Go to original source...
    3. Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1 726 men. Urology 1995; 46: 773-778. Go to original source... Go to PubMed...
    4. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density. A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-816. Go to original source... Go to PubMed...
    5. Canto El, Singh H, Shariat SF. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostatě cancer detection. J Urol 2004; 172: 900-904. Go to original source... Go to PubMed...
    6. Canto El, Singh H, Shariat SF. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004; 63: 905-910. Go to original source... Go to PubMed...
    7. Carter HB, Epstein JI, Chan DW. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997; 277: 1456-1460. Go to original source...
    8. Carter HB, Morrell CH, Pearson JD. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323-3328.
    9. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2-4 ng/ml. J Urol 2003; 170: 2181-2185. Go to original source... Go to PubMed...
    10. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama 1998; 279: 1542-1547. Go to original source... Go to PubMed...
    11. Catalona WJ, Richie JP, deKernion JB et al. Comparison of prostate specific antigen concentration versus prostatě specific antigen density in the early detection of prostatě cancer: receiver operating characteristic curves. J Urol 1994; 152: 2031-2036. Go to original source... Go to PubMed...
    12. Catalona WJ, Smith DS, Ornstein DK. Prostate Cancer detection in men with serum PSA concentrations of 2,6 to 4,0 ng/ml and benign prostate examination: Enhacement of specifity with free PSA measurements. JAMA 1997; 277: 1452-1455. Go to original source... Go to PubMed...
    13. Coley CM, Barry MJ, Fleming C. Early detection of prostate cancer: prior propability and effectiveness of tests. Ann Internal Med 1997; 126: 394-399. Go to original source... Go to PubMed...
    14. Darson MF, Pacelli A, Roche P, et al. Human glandular kallikrein 2 (nK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997; 49: 857-862. Go to original source... Go to PubMed...
    15. Djavan B, Zlotta AR, Byttebier G. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998; 160: 411-418. Go to original source...
    16. Eastham JA, May RA, Whatley. Clinical characteristics and biopsy specimen features in african-american and white men without prostate cancer. J. Natl Cancer Inst 1998; 90: 756-760. Go to original source... Go to PubMed...
    17. Etzioni R, Shen Y, Petteway JC, Brawer MK. Age-specific prostate-specific antigen: a reassessment. Prostate Suppl 1996; 7: 70-77. Go to original source... Go to PubMed...
    18. Horninger W, Cheli CD, Babaian RJ et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2-4 nanograms per milliliter. Urology 2002; 60(Suppl. 1): 31-35. Go to original source... Go to PubMed...
    19. Jemal A, Siegel R, Ward E, MurrayT, Xu J, Thun MJ. Cancer statistics, 2007. CA CancerJCIin 2007; 57: 43-66.
    20. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. JNatl Cancer Inst 1998; 90: 766-771. Go to original source... Go to PubMed...
    21. Kawaciuk I, Průša R. Atypické formy PSA v diagnostice karcinomu prostaty. Vybrané otázky z onkologie III. Praha: Galén, 1999: 17-18.
    22. Lin DW, Gold MH, Ransom S, Ellis WJ, Brawer MK. Transition zene prostate specific antigen density. Lack of use in prediction of prostatic carcinoma. J Urol 1998; 160: 77-81. Go to original source... Go to PubMed...
    23. Mettlin C, Littrup PJ, Kane RA, et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project Cancer 1994; 74: 1615-1620. Go to original source...
    24. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002; 59: 797-802. Go to original source... Go to PubMed...
    25. Mikolajczyk SD, Millar LS, Wang TJ. BPSA1, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000; 55: 41-45. Go to original source... Go to PubMed...
    26. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK. Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997; 157: 2183-2190. Go to original source... Go to PubMed...
    27. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Preoperative serum prostatě specifíc antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol; 2000; 164: 1596-1600. Go to original source... Go to PubMed...
    28. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranging PSA. Jama 1993; 270: 860-864. Go to original source... Go to PubMed...
    29. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-848. Go to original source... Go to PubMed...
    30. Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ ml. EurUrol 2006; 49: 293-302. Go to original source...
    31. Sokoli U, Chan DW, Mikolajczyk SD et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 2003; 61: 274-276. Go to original source... Go to PubMed...
    32. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159: 5-12. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.